Drug profile · INN
eplontersen
WAINZUA
eplontersen (WAINZUA) is a transthyretin antisense inhibitor.
EMA: approved Nervous system (N07) N07XX21
Patents linked 0
Pipeline programs 3
News articles 1
Drug details — eplontersen
- Class
- Nervous system (N07)
- Route
- —
- Patents
- 0
- Programs
- 3
- Data quality
- 0.83
Quick answer
eplontersen (WAINZUA) is a transthyretin antisense inhibitor.
Key facts
INN eplontersen
Brand WAINZUA
Mechanism Transthyretin antisense inhibitor
Target Transthyretin mRNA
Therapeutic class Nervous system (N07)
ATC code N07XX21
Mechanism of action
Transthyretin antisense inhibitor
Primary target: Transthyretin mRNA
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is eplontersen?
eplontersen (WAINZUA) is a transthyretin antisense inhibitor.
What is the brand name for eplontersen?
WAINZUA is a marketed brand name for eplontersen. Check FDA Drugs@FDA for the current US label holder and prescribing information.